B+
Bull case
25%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
FENC
FennecDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The best supported bullish read is that PEDMARK is already showing real commercial traction: first-quarter 2026 revenue grew 73% year over year to $15.1 million, demand in April was described as a record, and management tied growth to deeper use at existing accounts plus new AYA accounts [#IR-2026-05-14]. The concurrent ASCO-related evidence package also gives Fennec a plausible path to broaden clinical relevance over time [#IR-2026-05-21].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.1.
What can break
Broader AYA/adult adoption is promising but still early; management-linked materials explicitly frame prospective evidence in these populations as still emerging [#IR-2026-05-21].
Momentum
82
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.80 · Bull $13.50 · Bear $6.20Analysis 2026-06-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $17.67
Why
Momentum82 · Δ7d -2.6
Value41 · Δ7d -0.0
Sentiment49 · Δ7d +11.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +11.1.
Contradictions & invalidation
- • Broader AYA/adult adoption is promising but still early; management-linked materials explicitly frame prospective evidence in these populations as still emerging [#IR-2026-05-21].
- • Commercial scaling is expensive: first-quarter 2026 selling and marketing expense increased sharply as Fennec expanded the field organization [#IR-2026-05-14].
- • The main bearish read is that Fennec remains a single-asset story with commercialization costs rising sharply as it scales.
Catalyst clock
2026-08-15
Q2 PEDMARK commercial durability after strong Q1
Lead driver: Sentiment · See AI snapshot
Momentum
82
9% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
-3.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
49
62% active weight
Current posture
7d trendImproving
Δ7d
+11.1
Δ21d
+3.7
Why this grade
Composite grade D. Momentum 81.9 / Value 41.2 / Sentiment 48.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-18. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$9.80
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.20
Analysis reference price unavailable
Analysis 2026-06-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$414.85M
Beta
0.77
Shares Out
35.07M
P/E (TTM) · Derived
-34.7
P/S (TTM)
6.60
P/FCF (TTM)
9.49
Rev YoY
+85.2%
EPS YoY
-147.6%
Gross Margin
+93.7%
Op Margin
-2.7%
Net Debt
-$36.79M
Current Ratio
5.85
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data